Therapy News and Research

RSS

Researchers identify new combination therapy that promotes cancer cell death

Researchers at the University of Pennsylvania School of Medicine identified a combination therapy as a way to sensitize resistant human cancer cells to a treatment currently being tested in clinical trials They propose that the therapy may help to selectively eliminate cancer cells while leaving healthy cells intact, providing a cancer treatment with fewer side effects.

17 Jul 2007

New hope for childhood cancer sufferers

Scientists investigating drug therapies for children with Acute Lymphoblastic Leukaemia (ALL) have presented new data demonstrating for the very first time that a small molecule called ABT-737 can increase the effectiveness of standard therapies.

17 Jul 2007

Analysis of diabetes drugs

Most oral medications prescribed for type 2 diabetes are similarly effective for reducing blood glucose, but the drug metformin is less likely to cause weight gain and may be more likely than other treatments to decrease so-called bad cholesterol, according to a report funded by HHS Agency for Healthcare Research and Quality.

17 Jul 2007

How children with brain tumors perform at school

While children who have had brain tumors perform worse in school than healthy kids, grades in foreign language are the most affected and girls have a harder time than boys in getting good grades, according to a study published in the July 17, 2007, issue of Neurology, the medical journal of the American Academy of Neurology.

17 Jul 2007

Gene analysis and biostatistics

Three-stage procedures offer an optimal relationship between costs and benefits in analysing genetic influences in diseases and therapies, a fact that has major practical importance for the ever growing number of gene analyses.

17 Jul 2007

FDA approves Demipulse and Demipulse Duo Generators for use in vagus nerve stimulation

Cyberonics, Inc. has announced that the Demipulse and Demipulse Duo Generators for use in Vagus Nerve Stimulation ("VNS") Therapy were approved by the United States Food and Drug Administration ("FDA") for commercial release.

17 Jul 2007

FDA approves gene test to detect spread of breast cancer into lymph nodes

Veridex, LLC, a Johnson & Johnson company, has announced U.S. Food and Drug Administration (FDA) approval of the first intra-operative and gene-based test to detect the spread of breast cancer into the lymph nodes.

17 Jul 2007

New hope for insulin dependent diabetes cure

A diagnosis of type I diabetes means a life sentence of medical follow-up.

17 Jul 2007

Paint helps surgeons see where a tumor begins and ends

A tumor paint developed by researchers at Seattle Children's Hospital Research Institute and Fred Hutchinson Cancer Research Center will help surgeons see where a tumor begins and ends more precisely by illuminating the cancerous cells.

16 Jul 2007

Sequential and combination chemotherapy equally effective in treating advanced colorectal cancer

Many patients with incurable advanced colorectal cancer could be offered a more gentle treatment strategy starting with a single chemotherapy drug, as an alternative to current standard initial combination chemotherapy, without compromising their survival.

16 Jul 2007

Nodal status is best predictor of outcome after neoadjuvant therapy for esophageal cancer

The number of lymph nodes that contain evidence of cancer is the best predictor of the effectiveness of adding chemotherapy and radiation to a treatment plan prior to surgery in individuals with oesophageal cancer, according to a study published last month in the Annals of Surgery.

16 Jul 2007

A suntan is the body's best effort to fend off ultraviolet light

For years, the official word on tanning has been … don't. Health organizations have driven home the message that the sun exposure needed to get a tan increases your chances of getting skin cancer.

16 Jul 2007

Co-operation between GSF and clinic improves outlook for sarcoma patients

Hyperthermia, combined with chemotherapy, improves the chances of healing and survival of patients with low-lying, soft tissue sarcomas. At the Annual General Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, the GSF scientist Prof. Dr Rolf D.

16 Jul 2007

Hope for cure for insulin-dependent diabetes

A diagnosis of type I diabetes means a life sentence of medical follow-up. While treatments have become simpler and less restrictive in recent years, they are still a burden, especially for young patients.

16 Jul 2007

Src inhibitors may prove beneficial in breast cancer therapy

Estrogen, which binds estrogen receptor alpha (ER-alpha), is a risk factor for breast cancer development.

13 Jul 2007

Sciton receives FDA approval for laser-assisted lipolysis and pulsed light treatment of wrinkles

Sciton has announced that the new ProLipo laser module received clearance from the U.S. Food and Drug Administration for laser-assisted lipolysis, and its BBL broadband pulsed light received clearance for the treatment of wrinkles.

13 Jul 2007

Discovery of one important function of junk DNA

Scientists have only recently begun to speculate that what's referred to as junk DNA , the 96 percent of the human genome that doesn't encode for proteins and previously seemed to have no useful purpose , is present in the genome for an important reason.

13 Jul 2007

New target for muscular dystrophy drug therapy

Researchers at the University of Pennsylvania School of Medicine report how the gene for utrophin, which codes for a protein very similar to dystrophin, the defective protein in Duchenne muscular dystrophy (DMD), puts the brakes on its own expression in muscle cells, thereby suggesting a new target for treatment.

13 Jul 2007

Clinical responses to antiretroviral drug therapy simulated for the first time

Treatment of HIV patients must balance the need to suppress viral replication against the harmful side effects and significant cost to the patient of antiretroviral therapy.

13 Jul 2007

NDA for Lubiprostone to treat irritable bowel syndrome with constipation

Sucampo Pharmaceuticals, Inc., has announced that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration to seek market approval of a lower strength of lubiprostone (8 mcg) to treat irritable bowel syndrome with constipation (IBS-C).

13 Jul 2007